Axxcess Wealth Management LLC decreased its position in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) by 12.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,239 shares of the company’s stock after selling 1,394 shares during the period. Axxcess Wealth Management LLC’s holdings in VanEck Pharmaceutical ETF were worth $929,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors also recently bought and sold shares of PPH. Avestar Capital LLC acquired a new stake in shares of VanEck Pharmaceutical ETF in the fourth quarter worth $4,284,000. Raymond James Financial Services Advisors Inc. increased its stake in shares of VanEck Pharmaceutical ETF by 462.4% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 18,148 shares of the company’s stock worth $1,477,000 after acquiring an additional 14,921 shares during the period. Independent Advisor Alliance increased its stake in shares of VanEck Pharmaceutical ETF by 100.8% in the fourth quarter. Independent Advisor Alliance now owns 98,473 shares of the company’s stock worth $7,939,000 after acquiring an additional 49,423 shares during the period. Private Client Services LLC acquired a new stake in shares of VanEck Pharmaceutical ETF in the fourth quarter worth $298,000. Finally, Assetmark Inc. increased its stake in shares of VanEck Pharmaceutical ETF by 107.5% in the fourth quarter. Assetmark Inc. now owns 5,485 shares of the company’s stock worth $446,000 after acquiring an additional 2,841 shares during the period.
VanEck Pharmaceutical ETF Price Performance
PPH stock traded up $0.65 during midday trading on Friday, hitting $93.28. 256,744 shares of the stock traded hands, compared to its average volume of 135,693. The firm has a market cap of $619.38 million, a P/E ratio of 21.04 and a beta of 0.72. VanEck Pharmaceutical ETF has a 1-year low of $74.05 and a 1-year high of $93.85. The stock’s fifty day simple moving average is $91.57 and its 200-day simple moving average is $89.08.
VanEck Pharmaceutical ETF Cuts Dividend
VanEck Pharmaceutical ETF Company Profile
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
Featured Articles
- Five stocks we like better than VanEck Pharmaceutical ETF
- How to Calculate Options Profits
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- How to Invest in the Best Canadian Stocks
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- What Are Trending Stocks? Trending Stocks Explained
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Want to see what other hedge funds are holding PPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report).
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.